Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Inclusion Criteria: * Histologically confirmed advanced solid tumor cancer for which no curativetherapy exists * Clinically stable CNS disease is allowed provided the following criteria are met: * No uncontrolled brain metastases or CNS involvement * No active seizures * On stable dose of antiseizure or steroid medication for at least 7 days before study enrollment * Performance status - ECOG 0-2 * At least 12 weeks * Absolute neutrophil count at least 1,500/mm\^3 * Hemoglobin at least 9 g/dL * Platelet count at least 100,000/mm\^3 * Bilirubin no greater than 1.5 mg/dL * AST/ALT no greater than 2.5 times upper limit of normal * Creatinine no greater than 1.5 mg/dL * Creatinine clearance at least 60 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No active infection * No other serious concurrent systemic disorders (including other malignancy) * No prior bone marrow or peripheral blood stem cell transplantation * No concurrent immunotherapy * See Disease Characteristics * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered * Prior carboplatin and/or etoposide allowed * No more than 2 prior courses of mitomycin * See Disease Characteristics * No concurrent hormonal therapy * At least 4 weeks since prior radiotherapy and recovered * Palliative radiotherapy involving less than 35% bone marrow reserve allowed if completed at least 2 weeks before study enrollment * No prior wide-field radiotherapy to 35% or more of bone marrow * No prior pelvic radiotherapy * No concurrent radiotherapy * At least 28 days since prior investigational agents * No other concurrent experimental medications